<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ethambutol: An overview</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ethambutol: An overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Ethambutol: An overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Drew, PharmD, MS, FCCP, FIDP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Bernardo, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 26, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">Ethambutol</a> is an antimycobacterial agent that is most commonly used in combination with other drugs in the treatment of tuberculosis [<a href="#rid1">1</a>]. It is also used as part of a combination regimen in the therapy of nontuberculous mycobacterial infections [<a href="#rid1">1,2</a>].</p><p>The American Thoracic Society (ATS), United States Centers for Disease Control and Prevention, and Infectious Disease Society of America statement on the treatment of tuberculosis, as well as other ATS guidelines, can be accessed through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.thoracic.org%2Fstatements%2F&amp;token=Pby%2FnGkMB8TdW5V6epNUr3SRsNf6YBT3Fr3MIDgZvpZGvZXjM5qSgaeGcxqQwZtc&amp;TOPIC_ID=478" target="_blank">ATS website</a>.</p><p class="headingAnchor" id="H2"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span>The mechanism of action of <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> is not completely known. There is evidence that the drug exerts its bacteriostatic activity by virtue of inhibition of arabinosyl transferase, an enzyme that polymerizes arabinose into arabinan and then arabinogalactan, a mycobacterial cell wall constituent. </p><p class="headingAnchor" id="H2046173647"><span class="h1">SPECTRUM OF ACTIVITY</span><span class="headingEndMark"> — </span>The antimicrobial activity of <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> is limited to mycobacteria. Most data regarding the clinical and in vitro activity of ethambutol derive from experience in patients with tuberculosis. Synergy of ethambutol against <em>M. tuberculosis</em> has been demonstrated in some in vitro models with other antimycobacterial drugs, such as <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, and fluoroquinolones. However, its primary role for treatment of <em>M. avium</em> complex in combination with macrolides is to delay macrolide resistance in these patients [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H3"><span class="h1">RESISTANCE</span><span class="headingEndMark"> — </span>The breakpoint for <em>M. tuberculosis</em> <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> susceptibility is &lt;2 mcg/mL; the breakpoint for ethambutol resistance is &gt;8 mcg/mL [<a href="#rid4">4</a>].</p><p><em>M. tuberculosis</em> resistance to <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> is due to random spontaneous genetic mutations, occurring at a rate of approximately 1 in 10<sup>7</sup> organisms. Mutations mediated primarily via mutations in the <em>embB</em> gene most commonly result in increased production of the enzyme arabinosyl transferase, which overwhelms the inhibitory effects of ethambutol [<a href="#rid5">5-7</a>]. (See  <a class="medical medical_review" href="/d/html/8027.html" rel="external">"Epidemiology and molecular mechanisms of drug-resistant tuberculosis"</a>.)</p><p>Primary (pretreatment) resistance rates of <em>M. tuberculosis</em> to <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> vary widely, depending largely on the population sampled and method used to detect resistance. In one report, resistance to ethambutol in the United States ranged from 0.9 to 4.2 percent (depending on the region of birth) [<a href="#rid8">8</a>]. The rate of ethambutol resistance in the United States increases in foreign-born individuals and, in general, is seen most frequently in isolates resistant to other first-line antituberculous agents.</p><p>In vitro resistance to <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> was reported in approximately 50 percent of nontuberculous mycobacterium (NTM) pulmonary isolates, most of which were <em>M. avium</em> complex (MAC) [<a href="#rid9">9</a>]. Despite a report of favorable treatment outcomes in patients with MAC lung disease with ethambutol MICs &lt;8 mcg/mL [<a href="#rid10">10</a>] (see  <a class="medical medical_review" href="/d/html/3755.html" rel="external">"Mycobacterium avium complex (MAC) infections in persons with HIV"</a> and  <a class="medical medical_review" href="/d/html/5341.html" rel="external">"Treatment of <i>Mycobacterium avium </i>complex pulmonary infection in adults"</a>), there is generally a lack of correlation of susceptibility and outcome in the treatment of this infection [<a href="#rid11">11,12</a>]. </p><p>Resistance rates are variable against other species of NTM. For example:</p><p class="bulletIndent1"><span class="glyph">●</span><em>Mycobacterium bovis</em> and <em>Mycobacterium kansasii </em>are usually inhibited by <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> concentrations that are achievable in the blood. However, in vitro standards for NTM are unavailable for <em>M. kansasii</em> [<a href="#rid13">13</a>]. Although <em>Mycobacterium marinum </em>is also commonly treated with ethambutol, routine susceptibility testing for this pathogen is not recommended [<a href="#rid14">14</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>MAC is also generally susceptible but may require higher concentrations (up to 10 microgram/mL). However, isolate susceptibility varies widely, ranging from 2 to 32 mcg/mL by broth microdilution [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>Mycobacterium abscessus</em>, <em>Mycobacterium fortuitum</em>, <em>Mycobacterium haemophilum,</em> and <em>Mycobacterium chelonae </em>are often highly resistant to <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> [<a href="#rid14">14</a>]. </p><p></p><p class="headingAnchor" id="H5"><span class="h1">PHARMACOKINETICS</span><span class="headingEndMark"> — </span>Approximately 80 percent of an <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> dose is absorbed after oral administration. Absorption is proportional to dose and is not significantly altered by food but is reduced by concomitant ingestion of <a class="drug drug_general" data-topicid="8499" href="/d/drug information/8499.html" rel="external">aluminum hydroxide</a>. Peak serum concentrations after repeated doses of 25 mg/kg are approximately 4 to 5 microgram/mL and occur between two and four hours after administration.</p><p>Because of its low degree of protein binding (6 to 30 percent), <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> undergoes wide distribution. However, cerebrospinal concentrations are low (1 to 2 microgram/mL) even in the presence of inflamed meninges [<a href="#rid15">15</a>] suggesting that an alternative drug be used in treatment of central nervous system tuberculosis. Higher concentrations have been reported in both epithelial lining fluid and alveolar cells than plasma with highest in alveolar cells (15-fold that of plasma) [<a href="#rid16">16</a>].<em> </em></p><p><a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">Ethambutol</a> is partially metabolized in the liver, with 50 to 80 percent of the drug excreted unchanged in the urine and 20 percent in the feces. The serum half-life of 2.5 to 3.6 hours may be prolonged to up to 10 hours in patients with end-stage kidney disease  (<a class="graphic graphic_table graphicRef55978" href="/d/graphic/55978.html" rel="external">table 1</a>) [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H6"><span class="h1">DOSING AND ADMINISTRATION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">Ethambutol</a> tablets are available in strengths of 100 and 400 mg. All regimens described below are used as part of combination therapy. For the treatment of tuberculosis, regimens other than daily should utilize directly observed therapy.</p><p>For the treatment of tuberculosis in adults, the recommended dose is rounded based on tablet strength, lean body weight, and desired frequency of administration  (<a class="graphic graphic_table graphicRef55978" href="/d/graphic/55978.html" rel="external">table 1</a>). </p><p>The frequency (daily versus intermittent) of <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> for the treatment of drug-susceptible tuberculosis is depended on the phase of therapy (intense versus continuation), patient population, and the need/ability to employ intermittent therapy [<a href="#rid18">18</a>]. Daily doses approximate 15 mg/kg, while twice and three-times weekly dosing approximate 35 to 50 mg/kg and 25 mg/kg, respectively.</p><p>For treatment of <em>M. avium</em> complex (MAC) pulmonary disease, recommended dosing is based on severity and/or response to prior therapy. Regimens are 15 mg/kg daily or 25 mg/kg three times weekly. Patients with nonsevere, nodular bronchiectatic disease may receive three-times weekly therapy and those with severe, cavitary disease or refractory to prior therapy should receive daily therapy [<a href="#rid19">19,20</a>]. Daily therapy is also recommended in HIV-coinfected patients with disseminated disease [<a href="#rid21">21</a>]. </p><p>Optimal dosing for nontuberculous mycobacterium other than MAC has not been determined. Despite the lack of correlation of treatment outcomes to susceptibility results, 15 mg/kg/day is generally recommended for <em>M. kansasii</em> pulmonary infections [<a href="#rid20">20,22,23</a>]. Similar lack of in vitro correlations and daily dosing recommendations apply to infections due to <em>Mycobacterium xenopi and Mycobacterium malmoense</em>. (See  <a class="medical medical_review" href="/d/html/3755.html" rel="external">"Mycobacterium avium complex (MAC) infections in persons with HIV"</a> and  <a class="medical medical_review" href="/d/html/5341.html" rel="external">"Treatment of <i>Mycobacterium avium </i>complex pulmonary infection in adults"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H8"><span class="h2">Liver failure</span><span class="headingEndMark"> — </span>No adjustment of the <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> dose is necessary in patients with hepatic failure.</p><p class="headingAnchor" id="H9"><span class="h2">Kidney insufficiency</span><span class="headingEndMark"> — </span>Approximately 50 to 80 percent of <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> is eliminated as unchanged drug via the kidneys. Therefore, dose adjustment is required in patients with severe kidney impairment to reduce the risk of toxicity (primarily ocular) [<a href="#rid24">24,25</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>Creatinine clearance ≥30 mL/minute − For patients with creatinine clearance ≥30 mL/minute, no dose adjustment is required. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Creatinine clearance &lt;30 mL/minute or intermittent hemodialysis − For patients with creatinine clearance &lt;30 mL/minute or requiring intermittent hemodialysis, a standard dose (ie, 15 to 25 mg/kg of estimated lean body weight for adults) should be administered three times weekly by directly observed therapy  (<a class="graphic graphic_table graphicRef55978" href="/d/graphic/55978.html" rel="external">table 1</a>) [<a href="#rid17">17,26,27</a>]. </p><p></p><p class="bulletIndent1">Patients requiring intermittent hemodialysis should receive the dose after dialysis. In one report of a patient undergoing high-flux hemodialysis, a mean 41 percent decrease in serum <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> concentration during dialysis was observed [<a href="#rid28">28</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peritoneal dialysis − Data to guide dosing for patients undergoing peritoneal dialysis are limited. Therefore, the initial dosing for such patients is the same as for those on intermittent hemodialysis. Adjustments should be based on serum concentration monitoring.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Continuous venovenous hemofiltration − Data to guide dosing for patients undergoing continuous venovenous hemofiltration are limited. Therefore, the initial dosing for such patients is the same as for those on intermittent hemodialysis. In one case report, adequate <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> concentrations were maintained [<a href="#rid29">29</a>]. Adjustments should be based on serum concentration monitoring.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum concentration monitoring − Issues related to serum concentration monitoring are discussed below. (See <a class="local">'Serum concentration monitoring'</a> below.) </p><p></p><p>Additional details are provided separately in the Lexicomp <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> drug monograph, available within UpToDate.</p><p class="headingAnchor" id="H10"><span class="h2">Children</span><span class="headingEndMark"> — </span>In general, serum concentrations observed in children are lower than adults when receiving comparable weight-based doses [<a href="#rid30">30</a>]. This may be due to enhanced drug clearance relative to adult patients [<a href="#rid31">31</a>]. Therefore, dosing of <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> (given in combination with other antimycobacterial agents) in infants, children, and adolescents &lt;15 years of age, weighing &lt;40 kg is 20 mg/kg (range 15 to 25) mg/kg daily or 50 mg/kg twice weekly [<a href="#rid18">18</a>]. </p><p>Since visual acuity and color perception changes are difficult to assess in young patients, <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> may be avoided in children without cavitating lesions whose visual acuity cannot be accurately assessed and/or at low risk of resistance to alternate primary treatments. However, the magnitude of risk posed by ethambutol to children in this setting is debated [<a href="#rid32">32</a>]. Therefore, the American Academy of Pediatrics recommends ethambutol as part of the intensive-phase regimen for children with tuberculosis even in the absence of risk factors for resistance [<a href="#rid18">18,33</a>]. </p><p class="headingAnchor" id="H11"><span class="h2">Pregnant and lactating patients</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">Ethambutol</a> is generally considered safe during pregnancy. (See  <a class="medical medical_review" href="/d/html/8014.html" rel="external">"Tuberculosis disease (active tuberculosis) in pregnancy"</a>.)</p><p>While limited data are available, maternal daily doses of up to 15 mg/kg have resulted in low concentrations in breast milk unlikely to cause harm in infants &gt;2 months of age [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Older adults</span><span class="headingEndMark"> — </span>Older adult patients may be more susceptible to the side effects of <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a>, especially if they are receiving higher doses. Since renal function declines with age, careful attention should be paid to the need for potential dose adjustment based upon renal function in this patient population.</p><p class="headingAnchor" id="H13"><span class="h2">Patients with HIV infection</span><span class="headingEndMark"> — </span>HIV patients receiving <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> in combination with <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> frequently demonstrate low maximum serum concentrations (observed with a daily dose of 20 mg/kg or 50 mg/kg twice weekly or 30 mg/kg thrice weekly) [<a href="#rid35">35,36</a>]. In HIV-coinfected children, reductions in ethambutol have been reported regardless of antiretroviral therapy (ART) [<a href="#rid37">37</a>]. Therefore, reductions in exposure in HIV-coinfected patients are unlikely due to drug interactions related to their ART.</p><p class="headingAnchor" id="H820775750"><span class="h2">Patients with obesity</span><span class="headingEndMark"> — </span>Established weight-based dosing guidelines utilize lean body weight. However, studies to determine the optimal dosing of <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> in obese patients are lacking. </p><p class="headingAnchor" id="H14"><span class="h1">ADVERSE REACTIONS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">Ethambutol</a> is generally well tolerated. Side effects are usually dose related and are more common when doses exceed 15 mg/kg.</p><p class="headingAnchor" id="H15"><span class="h2">Visual changes</span><span class="headingEndMark"> — </span>Optic neuropathy (usually manifested as a change in visual acuity or red-green color blindness) is the most important <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> toxicity. As discussed previously, reports of ocular toxicity in children of all ages receiving ethambutol at doses of from 15 to 30 mg/kg documented are rare. In adults, the incidence of ocular toxicity occurred at &gt;40 percent at doses of &gt;50 mg/kg/day and 0 to 3 percent at a dose of 15 mg/kg/day [<a href="#rid38">38</a>]. In other reports, the incidence of optic neuropathy when ethambutol is taken for more than two months is 18 percent in subjects receiving more than 35 mg/kg per day, 5 to 6 percent with 25 mg/kg per day, and less than 1 percent with 15 mg/kg per day [<a href="#rid39">39</a>]. The increased incidence seen in patients with nontuberculous mycobacterium is most likely related to longer treatment durations [<a href="#rid20">20</a>]. Intermittent dosing has also been associated with a reduced incidence of reaction [<a href="#rid40">40,41</a>]. In a study of 229 patients treated with ethambutol for pulmonary <em>M. avium</em> complex (MAC) disease, the incidence of ocular toxicity, confirmed by an ophthalmologist, in those treated with daily ethambutol (25 mg/kg per day for two months, then 15 mg/kg per day) compared to intermittent therapy (25 mg/kg three days a week) was 6 versus 0 percent, respectively [<a href="#rid38">38</a>]. Ocular toxicity may be more common in patients with MAC when compared with those with tuberculosis due to longer durations of therapy.</p><p>Optic neuritis is reversible in most patients.</p><p class="headingAnchor" id="H16"><span class="h2">Other reactions</span><span class="headingEndMark"> — </span>Hematologic (neutropenia, thrombocytopenia), gastrointestinal (nausea, vomiting, abdominal pain, hepatotoxicity), central nervous system (headache, dizziness, confusion), and cutaneous reactions occur infrequently but may be more common in patients receiving concomitant <a class="drug drug_general" data-topicid="9438" href="/d/drug information/9438.html" rel="external">ethionamide</a> therapy.</p><p><a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">Ethambutol</a>, when used in combination with <a class="drug drug_general" data-topicid="9836" href="/d/drug information/9836.html" rel="external">pyrazinamide</a> for the treatment of latent tuberculosis in patients exposed to multidrug-resistant strains, has been associated with a high incidence of hepatotoxicity or gastrointestinal intolerance leading to discontinuation of therapy (approximately 60 percent of treated subjects in one report) [<a href="#rid42">42</a>].</p><p>Infrequently, <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> has been associated with eosinophilia and systemic symptoms [<a href="#rid43">43</a>]. In most of the existing reports, it was difficult to establish the unique contribution ethambutol played in such a reaction due to the concomitant administration of other first-line antituberculous agents. </p><p class="headingAnchor" id="H17"><span class="h1">MONITORING</span></p><p class="headingAnchor" id="H1971549346"><span class="h2">Clinical monitoring</span><span class="headingEndMark"> — </span>It is generally recommended that patients receiving <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> as part of combination therapy for treatment of a mycobacterial infection undergo baseline Snellen visual acuity and red-green color perception testing. All patients should be advised of the side effects associated with ethambutol, most notably those associated with the development of optic neuritis. The need for routine periodic visual acuity testing during therapy is controversial, especially if a dose of 15 mg/kg is chosen, but patients noting changes in their vision should be referred to an ophthalmologist for careful monitoring. In all patients receiving combination therapy for tuberculosis or MAC infections, baseline blood counts, serum chemistry, and liver function studies should be obtained and repeated in the event of suspected drug-related toxicity.</p><p class="headingAnchor" id="H521595527"><span class="h2">Serum concentration monitoring</span><span class="headingEndMark"> — </span>In general, there are minimal data to correlating <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> serum concentrations and treatment outcome [<a href="#rid44">44</a>]<em>.</em> Therefore,<em> </em>there is no role for routine serum concentration monitoring. </p><p>Circumstances in which serum concentration monitoring may be useful to guide dosing include kidney insufficiency, suspected malabsorption, or therapeutic failure. </p><p>Target peak (2 hours postdose) concentrations after daily doses of 15 to 25 mg/kg are between 2 and 6 micrograms/mL. Since absorption may be delayed or impaired in some patients, a second sample (6 hours after dosing) is recommended by some in order to aid in better characterizing the true peak concentration [<a href="#rid25">25</a>]. </p><p class="headingAnchor" id="H18"><span class="h1">DRUG INTERACTIONS</span><span class="headingEndMark"> — </span>Details about specific interactions may be obtained by using the <a class="external" href="/drug-interactions">drug interactions tool</a> included within UpToDate.</p><p class="headingAnchor" id="H1564659"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">Ethambutol</a> is an antimycobacterial agent that is most commonly used in combination with other drugs in the treatment of tuberculosis. It is also used as part of a combination regimen in the therapy of <em>Mycobacterium avium</em> complex (MAC) infections in patients with or without concomitant infection with human immunodeficiency virus (HIV). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The mechanism of action of <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> is not completely understood. There is evidence that ethambutol exerts its bacteriostatic activity through inhibition of arabinosyl transferase, an enzyme that plays an important role in mycobacterial cell wall formation. (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The antimicrobial activity of <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> is limited to mycobacteria. Synergy of ethambutol with other antimycobacterial drugs, such as <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> and fluoroquinolones, has been demonstrated in vitro against <em>M. tuberculosis</em>. Ethambutol has variable activity against nontuberculous mycobacteria. (See <a class="local">'Spectrum of activity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">Ethambutol</a> is well absorbed after oral administration. Because of its low degree of protein binding, ethambutol undergoes wide distribution. However, cerebrospinal concentrations are low (even in the presence of inflamed meninges). (See <a class="local">'Pharmacokinetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The dose of <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> is dependent upon body weight, frequency of administration, and indication. (See <a class="local">'Dosing and administration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No adjustment of the <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> dose is necessary in patients with hepatic failure. For patients with creatinine clearances &lt;30 mL/min or receiving intermittent hemodialysis, the dosing interval for ethambutol should be extended from 24 to 36 hours. A small amount of ethambutol is removed by hemodialysis and doses should be administered after dialysis in these patients. (See <a class="local">'Special populations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">Ethambutol</a> is generally considered safe during pregnancy. (See <a class="local">'Pregnant and lactating patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Optic neuropathy (usually manifested as a change in visual acuity or red-green color blindness) is the most important <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> toxicity. The reported incidence of optic neuropathy when ethambutol is taken for more than two months increases with higher dosing of the drug. Optic neuritis is reversible in most patients. (See <a class="local">'Visual changes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It is generally recommended that patients receiving <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> as part of combination therapy for treatment of a mycobacterial infection undergo baseline Snellen visual acuity and red-green color perception testing. (See <a class="local">'Monitoring'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Lewis ML. Ethambutol. In: Antimicrobial Therapy and Vaccines, Yu V, Merigan T, Barriere S (Eds), Williams &amp; Wilkins, Baltimore 1998.</li><li><a class="nounderline abstract_t">Daley CL, Iaccarino JM, Lange C, et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis 2020; 71:e1.</a></li><li><a class="nounderline abstract_t">Moon SM, Park HY, Kim SY, et al. Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease. Antimicrob Agents Chemother 2016; 60:6758.</a></li><li class="breakAll">https://clsi.org/media/2624/m62ed1_sample.pdf (Accessed on January 21, 2022).</li><li><a class="nounderline abstract_t">Telenti A, Philipp WJ, Sreevatsan S, et al. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med 1997; 3:567.</a></li><li><a class="nounderline abstract_t">Belanger AE, Besra GS, Ford ME, et al. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci U S A 1996; 93:11919.</a></li><li><a class="nounderline abstract_t">Dookie N, Rambaran S, Padayatchi N, et al. Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care. J Antimicrob Chemother 2018; 73:1138.</a></li><li><a class="nounderline abstract_t">Furukawa NW, Haider MZ, Allen SJ, et al. Resistance to First-Line Antituberculosis Drugs in Washington State by Region of Birth and Implications for Latent Tuberculosis Treatment Among Foreign-Born Individuals. Am J Trop Med Hyg 2017; 96:543.</a></li><li><a class="nounderline abstract_t">Abate G, Stapleton JT, Rouphael N, et al. Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial Disease. Clin Infect Dis 2021; 72:1127.</a></li><li><a class="nounderline abstract_t">Kwon BS, Kim MN, Sung H, et al. In Vitro MIC Values of Rifampin and Ethambutol and Treatment Outcome in Mycobacterium avium Complex Lung Disease. Antimicrob Agents Chemother 2018; 62.</a></li><li><a class="nounderline abstract_t">Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med 1994; 121:905.</a></li><li><a class="nounderline abstract_t">Sison JP, Yao Y, Kemper CA, et al. Treatment of Mycobacterium avium complex infection: do the results of in vitro susceptibility tests predict therapeutic outcome in humans? J Infect Dis 1996; 173:677.</a></li><li class="breakAll">Clinical and Laboratory Standards Institute. 2018. Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes, 3rd ed, CLSI standard document M24. Clinical and Laboratory Standards Institute, Wayne, PA.</li><li><a class="nounderline abstract_t">Brown-Elliott BA, Woods GL. Antimycobacterial Susceptibility Testing of Nontuberculous Mycobacteria. J Clin Microbiol 2019; 57.</a></li><li><a class="nounderline abstract_t">Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb) 2010; 90:279.</a></li><li><a class="nounderline abstract_t">McCallum AD, Pertinez HE, Else LJ, et al. Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis. Clin Infect Dis 2021; 73:e3365.</a></li><li><a class="nounderline abstract_t">Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.</a></li><li><a class="nounderline abstract_t">Nahid P, Dorman SE, Alipanah N, et al. Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:853.</a></li><li><a class="nounderline abstract_t">Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J 2020; 56.</a></li><li><a class="nounderline abstract_t">Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 2017; 72:ii1.</a></li><li class="breakAll">Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Available at: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines (Accessed on July 25, 2023).</li><li><a class="nounderline abstract_t">Research Committee of the British Thoracic Society. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 2001; 56:167.</a></li><li><a class="nounderline abstract_t">Harris GD, Johanson WG, Nicholson DP. Response to chemotherapy of pulmonary infection due to Mycobacterium kansasii. Am Rev Respir Dis 1975; 112:31.</a></li><li><a class="nounderline abstract_t">Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 1984; 9:511.</a></li><li><a class="nounderline abstract_t">Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 2014; 74:839.</a></li><li><a class="nounderline abstract_t">Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med 2019; 200:e93.</a></li><li class="breakAll">US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf (Accessed on December 02, 2021).</li><li><a class="nounderline abstract_t">Chew R, Jongbloed S, Jegatheesan D, et al. Ethambutol Is Cleared by a Contemporary High-Flux Hemodialyzer, and Drug Monitoring Ensures Safety and Therapeutic Effect. Antimicrob Agents Chemother 2017; 61.</a></li><li><a class="nounderline abstract_t">Sin JH, Elshaboury RH, Hurtado RM, et al. Therapeutic drug monitoring of antitubercular agents for disseminated Mycobacterium tuberculosis during intermittent haemodialysis and continuous venovenous haemofiltration. J Clin Pharm Ther 2018; 43:291.</a></li><li><a class="nounderline abstract_t">Yang H, Enimil A, Gillani FS, et al. Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children. Pediatr Infect Dis J 2018; 37:43.</a></li><li><a class="nounderline abstract_t">Panjasawatwong N, Wattanakul T, Hoglund RM, et al. Population Pharmacokinetic Properties of Antituberculosis Drugs in Vietnamese Children with Tuberculous Meningitis. Antimicrob Agents Chemother 2020; 65.</a></li><li><a class="nounderline abstract_t">Trébucq A. Should ethambutol be recommended for routine treatment of tuberculosis in children? A review of the literature. Int J Tuberc Lung Dis 1997; 1:12.</a></li><li><a class="nounderline abstract_t">Holmberg PJ, Temesgen Z, Banerjee R. Tuberculosis in Children. Pediatr Rev 2019; 40:168.</a></li><li class="breakAll">Drugs and Lactation Database (LactMed), National Library of Medicine (US), Bethesda (MD) 2006.</li><li><a class="nounderline abstract_t">Perlman DC, Segal Y, Rosenkranz S, et al. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin Infect Dis 2005; 41:1638.</a></li><li><a class="nounderline abstract_t">Daskapan A, Idrus LR, Postma MJ, et al. A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs. Clin Pharmacokinet 2019; 58:747.</a></li><li><a class="nounderline abstract_t">Jacobs TG, Svensson EM, Musiime V, et al. Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review. J Antimicrob Chemother 2020; 75:3433.</a></li><li class="breakAll">World Health Organization. Ethambutol efficacy and toxicity: literature review and recommendations for daily and intermittent dosage in children. http://apps.who.int/iris/bitstream/handle/10665/69366/WHO_HTM_TB_2006.365_eng.pdf;jsessionid=2C3D18BDA8CD999C009EDCE48BB016B6?sequence=1 (Accessed on June 08, 2021).</li><li><a class="nounderline abstract_t">Leibold JE. The ocular toxicity of ethambutol and its relation to dose. Ann N Y Acad Sci 1966; 135:904.</a></li><li><a class="nounderline abstract_t">Griffith DE, Brown-Elliott BA, Shepherd S, et al. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2005; 172:250.</a></li><li><a class="nounderline abstract_t">Kwak N, Park J, Kim E, et al. Treatment Outcomes of Mycobacterium avium Complex Lung Disease: A Systematic Review and Meta-analysis. Clin Infect Dis 2017; 65:1077.</a></li><li><a class="nounderline abstract_t">Younossian AB, Rochat T, Ketterer JP, et al. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J 2005; 26:462.</a></li><li><a class="nounderline abstract_t">Allouchery M, Logerot S, Cottin J, et al. Antituberculosis Drug-Associated DRESS: A Case Series. J Allergy Clin Immunol Pract 2018; 6:1373.</a></li><li><a class="nounderline abstract_t">Sileshi T, Tadesse E, Makonnen E, Aklillu E. The Impact of First-Line Anti-Tubercular Drugs' Pharmacokinetics on Treatment Outcome: A Systematic Review. Clin Pharmacol 2021; 13:1.</a></li></ol></div><div id="topicVersionRevision">Topic 478 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Lewis ML. Ethambutol. In: Antimicrobial Therapy and Vaccines, Yu V, Merigan T, Barriere S (Eds), Williams &amp; Wilkins, Baltimore 1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32628747" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27572413" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27572413" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9142129" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8876238" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29360989" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27994106" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Resistance to First-Line Antituberculosis Drugs in Washington State by Region of Birth and Implications for Latent Tuberculosis Treatment Among Foreign-Born Individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32198521" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30012759" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : In Vitro MIC Values of Rifampin and Ethambutol and Treatment Outcome in Mycobacterium avium Complex Lung Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7978715" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8627032" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Treatment of Mycobacterium avium complex infection: do the results of in vitro susceptibility tests predict therapeutic outcome in humans?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8627032" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Treatment of Mycobacterium avium complex infection: do the results of in vitro susceptibility tests predict therapeutic outcome in humans?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31315954" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Antimycobacterial Susceptibility Testing of Nontuberculous Mycobacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20709598" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cerebrospinal fluid concentrations of antituberculosis agents in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32856694" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27516382" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27621353" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32636299" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29054853" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29054853" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11182006" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1147382" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Response to chemotherapy of pulmonary infection due to Mycobacterium kansasii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6391781" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical pharmacokinetics of the antituberculosis drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24846578" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Therapeutic drug monitoring in the treatment of tuberculosis: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31729908" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31729908" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28396542" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Ethambutol Is Cleared by a Contemporary High-Flux Hemodialyzer, and Drug Monitoring Ensures Safety and Therapeutic Effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28895161" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Therapeutic drug monitoring of antitubercular agents for disseminated Mycobacterium tuberculosis during intermittent haemodialysis and continuous venovenous haemofiltration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28719501" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33139294" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Population Pharmacokinetic Properties of Antituberculosis Drugs in Vietnamese Children with Tuberculous Meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9441051" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Should ethambutol be recommended for routine treatment of tuberculosis in children? A review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30936398" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Tuberculosis in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30936398" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Tuberculosis in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16267738" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30406475" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32785712" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32785712" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5220245" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The ocular toxicity of ethambutol and its relation to dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15860751" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28582488" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Treatment Outcomes of Mycobacterium avium Complex Lung Disease: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135729" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29274824" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Antituberculosis Drug-Associated DRESS: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33469389" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The Impact of First-Line Anti-Tubercular Drugs' Pharmacokinetics on Treatment Outcome: A Systematic Review.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
